39th week of 2011 patent applcation highlights part 57 |
Patent application number | Title | Published |
20110237579 | INHIBITORS OF HCV NS5A - The invention relates to non-macrocyclic, non-peptidic, substituted heterocyclic compounds useful for inhibiting hepatitis C virus (“HCV”) replication, particularly functions of the non-structural 5A (“NS5A”) protein of HCV | 2011-09-29 |
20110237580 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS - The present invention is concerned with novel substituted bicyclic imidazole derivatives of Formula (I) | 2011-09-29 |
20110237581 | DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) - A compound having the structure set forth in Formula (I) and Formula (II): | 2011-09-29 |
20110237582 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE - This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2011-09-29 |
20110237583 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER - The present invention relates to pyridopyrimidine derivatives according to formula (I) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers. | 2011-09-29 |
20110237584 | KYNURENINE PRODUCTION INHIBITOR - Provided is a kynurenine production inhibitor comprising a nitrogen-containing heterocyclic compound represented by formula (I): | 2011-09-29 |
20110237585 | SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 2011-09-29 |
20110237586 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE - The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention relates to compounds of the formula I: | 2011-09-29 |
20110237587 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same - Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same. | 2011-09-29 |
20110237588 | Thienylpyri(mi)dinylazole - Thienylpyri(mi)dinylazole of the formula (I) | 2011-09-29 |
20110237589 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS - The present invention relates to guanidine compounds of the general formula I | 2011-09-29 |
20110237590 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE - To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjögren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): | 2011-09-29 |
20110237591 | Plant Protection Formulations Comprising Dimethomorph and Dithiocarbamate - The present invention relates to fungicidal plant protection formulations comprising:
| 2011-09-29 |
20110237592 | SUBSTITUTED AMIDO PHENOXYBENZAMIDES - The present invention relates to substituted amido phenoxybenzamide compounds of general formula (I): | 2011-09-29 |
20110237593 | TOPICAL ANTI-PRURITIC COMPOSITIONS AND METHODS OF ACTION OF SAME - Topical anti-pruritic compositions and methods of using the same to treat pruritus. These anti-pruritic compositions are capable of temporarily or permanently reducing, inhibiting, treating, ameliorating, and/or preventing pruritic skin conditions, as well as other related skin conditions. In a particular aspect, the present formulations provide a quicker and more effective treatment of pruritus than do certain present pruritus-treating compositions. | 2011-09-29 |
20110237594 | FUNGICIDE HERETOCYCLYL-TRIAZINYL-AMINO DERIVATIVES - The present invention relates to heterocyclyl-triazinyl-amino derivatives of formula (I) | 2011-09-29 |
20110237595 | DERIVATIVES OF HETEROARYL-ALKYLCARBAMATES, METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS - The present invention is directed to compounds and compositions for the treatment of neurological diseases that cause neurogenic and neuropathic pain, inflammatory diseases, renal ischaemia, cardiovascular disease and other pathologies caused by the presence of endogenous cannabinoids and or other substrates resulting from the metabolic activities of fatty acid amido hydrolase (FAAH). These compounds are represented by the formula (I): | 2011-09-29 |
20110237596 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE - Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis). | 2011-09-29 |
20110237597 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY - Methods for treatment of peripheral nerve sensory loss are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity. | 2011-09-29 |
20110237598 | NEW COMPOUNDS - The present invention encompasses compounds of general formulae (1 | 2011-09-29 |
20110237599 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as inhibitors of H | 2011-09-29 |
20110237600 | COMPOUNDS FOR IMPROVING LEARNING AND MEMORY - The present invention provides a compound of Formula I: (I) and methods for improving memory in a subject by administering a therapeutically effective amount of the compound. | 2011-09-29 |
20110237601 | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists - The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: | 2011-09-29 |
20110237602 | METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES - The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof. | 2011-09-29 |
20110237603 | COMPOSITIONS OF AZIMILIDE DIHYDROCHLORIDE - The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof. | 2011-09-29 |
20110237604 | METHODS FOR PREVENTING OR TREATING CARDIAC ARRHYTHMIA - Disclosed are methods of preventing or treating cardiac arrhythmia comprising administering to a mammal in need thereof, such as a human, an effective amount of vanoxerine (GBR 12909) or a pharmaceutically acceptable salt, derivative or metabolite thereof. | 2011-09-29 |
20110237605 | Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative - A molecular crystal form of (S)-3-(2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin- | 2011-09-29 |
20110237606 | 3-Deazaneplanocin Derivatives - This invention describes the series of compounds based on the 3-deazaneplanocin A (DZNep) core structure designed to inhibit the function of Polycomb repressive complex 2 (PRC2) proteins. | 2011-09-29 |
20110237607 | SUBSTITUTED PURINYL-PYRAZOL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel substituted purinyl-pyrazol derivatives (I) and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels. | 2011-09-29 |
20110237608 | Pyridopyrimidinone Inhibitors of PI3Kalpha - The invention is directed to Compounds of Formula I: | 2011-09-29 |
20110237609 | ANTIFOLATE COMPOSITIONS - The present invention provides pharmaceutical compositions comprising an antifolate compound. The compositions can be prepared such that unit dosages of the composition exhibit excellent API content uniformity, such as by wet granulation or hot melt granulation. The pharmaceutical compositions are useful in the treatment of multiple conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis. | 2011-09-29 |
20110237610 | Quinazoline Derivatives as Antiproliferative Agents - The invention concerns quinazoline derivatives of Formula I | 2011-09-29 |
20110237611 | CHEMICAL PERMEATION ENHANCERS ENHANCE NERVE BLOCKADE BY TOXINS - Chemical permeation enhancers (CPEs) improve access of local anesthetics to the nerve, thereby improving their performance. Surfactants, representing three CPE sub-groups: anionic, cationic, and nonionic surfactants, were co-injected with tetrodotoxin (TTX) or bupivacaine at the sciatic nerve of Sprague-Dawley rats. All enhancers produced marked concentration-dependent improvements in the frequency and duration of block with TTX but not bupivacaine. An in vitro toxicity assay showed a wide range of CPE myotoxicity, but in vivo histological assessment showed no signs of muscle or nerve damage at concentrations of CPEs that produced a half-maximal increase in the duration of block of TTX. There was no systematic relationship between the enhancers' charge or hydrophobicity and their enhancement of block duration or potency. Thus, CPEs can provide marked prolongation of nerve blockade from TTX, without apparent local tissue toxicity, and therefore enhance the clinical applicability of TTX for prolonged-duration local anesthesia. | 2011-09-29 |
20110237612 | Thienylamino pyrimidines for use as Fungicides - Thienylaminopyrimidines of the formula (I) | 2011-09-29 |
20110237613 | DHA ESTERS AND USE THEREOF IN TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE - The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation. | 2011-09-29 |
20110237616 | PHEHYLEPHRINE FORMULATIONS WITH IMPROVEDS STABILITY - A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity. | 2011-09-29 |
20110237617 | THIENO[2,3-C] ISOQUINOLINES FOR USE AS INHIBITORS OF PARP - The present invention relates to compounds for the inhibition of poly(ADP-ribose) polymerase (PARP). In some embodiments, the compounds have the Formula: | 2011-09-29 |
20110237618 | METHODS FOR TREATING MIGRAINES WITH HUPERZINE A DERIVATIVES - The present invention relates to a method for treating, alleviating, or preventing pain, particularly migraines, functional pain syndrome, or organic pain syndrome, by administering to a patient in need thereof compound (I), or salts thereof, or pharmaceutical preparations thereof comprising mixtures of compound (I) or salts thereof with pharmaceutically-acceptable diluents | 2011-09-29 |
20110237619 | IMIDAZOPYRIDINE DERIVATIVES WHICH INHIBIT THE SECRETION OF GASTRIC ACID - The present invention relates to substituted imidazo[1,2-a]pyridines of formula I where R is —CH | 2011-09-29 |
20110237620 | HETEROCYCLIC COMPOUND AND USE THEREOF - A compound represented by formula (I) or a salt thereof, which has a potent Raf inhibitory activity. | 2011-09-29 |
20110237621 | Macrocyclic Inhibitors of Hepatitis C Virus - Inhibitors of HCV replication of formula (I) | 2011-09-29 |
20110237622 | RENIN INHIBITORS - The present invention relates to 3,4-substituted piperidinyl—based renin inhibitor compounds bearing at 4-position oxopyridine or Isoquinolone and having the formula (I): wherein S is Formula (IIa) or Formula (IIb). The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency. | 2011-09-29 |
20110237623 | SUSTAINED-RELEASE DONEPEZIL FORMULATION - A sustained-release formulation for an acetylcholinesterase inhibitor, comprising an acetylcholinesterase inhibitor and at least two gel-forming polymers, and methods of manufacture thereof. The acetylcholinesterase inhibitor preferably comprises donepezil. | 2011-09-29 |
20110237624 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS - The present invention relates to compounds of formula (I): | 2011-09-29 |
20110237625 | SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-a MODULATORS - The present invention relates to compounds of Formula (I), | 2011-09-29 |
20110237626 | COMPOSITIONS FOR HYGIENIC HAND DISINFECTION AND DISINFECTANT HANDWASHING - The invention relates to a disinfectant composition which includes a) one or more 1- or 2-(C | 2011-09-29 |
20110237627 | METHODS OF SYNTHESIZING ANATABINE - Anatabine is obtained by reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene-pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis-1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. The resulting anatabine is substantially free from contaminants and displays good stability. In an alternative embodiment, the benzylhydrylidene-pyridin-3-yl-methyl-amine may be used in the synthesis of other alkaloids such as anabasine, nornicotine, N-methylanabasine, and anabaseine. | 2011-09-29 |
20110237628 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES - This invention relates to novel cyclopentyl- and cycloheptylpyrazole derivatives of the formula I | 2011-09-29 |
20110237629 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF - The present application relates to amino acid ester prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-oxazol-4-yl]methyl}sulfanyl)-4-(4-{[2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitriles, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders. | 2011-09-29 |
20110237630 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF - A compound represented by the formula (I) | 2011-09-29 |
20110237631 | Selective Glycosidase Inhibitors and Uses Thereof - The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcN Ac. | 2011-09-29 |
20110237632 | ANTIFOULING COMBINATION COMPRISING 4-BROMO-2-(4- CHLOROPHENYL)-5-(TRIFLUOROMETHYL)-1H-PYRROLE-3-CARBONITRILE - The present invention relates to combinations of 4-bromo-2-(4-chloro-phenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, and the biocidal compound 2-butyl-1,2-benzisothiazol-3(2H)one (butylBIT), or a salt thereof, which provide an improved protecting effect against fouling organisms. More particularly, the present invention relates to compositions comprising a combination of 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, together with the biocidal compound butylBIT; in respective proportions to provide a synergistic effect against fouling organisms and the use of these compositions for protecting materials against fouling organisms. | 2011-09-29 |
20110237633 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY - The present invention provides compounds and pharmaceutically acceptable compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which hepatocyte growth factor/scatter factor (HGF/SF) or the activities thereof, or agonists or antagonists thereof, have a therapeutically useful role. | 2011-09-29 |
20110237634 | NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 - Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment. | 2011-09-29 |
20110237635 | TETRAHYDRONAPHTHALENE DERIVATIVES - This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formulae, in one embodiment: | 2011-09-29 |
20110237636 | Hepatitis C Virus Inhibitors - This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. | 2011-09-29 |
20110237637 | METRONIDAZOLE-BASED DERMATOLOGICAL FOAM AND EMULSIONS FOR THE PRODUCTION THEREOF - Oil-in-water emulsions expandable into stable foams having diminished inhibitor of skin breathing and useful for the treatment of dermatological conditions/afflictions, e.g., rosacea, advantageously contain:
| 2011-09-29 |
20110237638 | METRONIDAZOLE-BASED DERMATOLOGICAL FOAM AND EMULSIONS FOR THE PREPARATION THEREOF - Oil-in-water emulsions expandable into stable foams having diminished inhibitor of skin breathing and useful for the treatment of dermatological conditions/afflictions, e.g., rosacea, advantageously contain:
| 2011-09-29 |
20110237639 | IMIDAZOLINYLMETHYL ARYL SULFONAMIDE - This invention relates to an alpha-1 A receptor partial agonist, which is represented by Formula I: | 2011-09-29 |
20110237640 | PYRAZOLE PHENYL DERIVATIVES - The invention relates to compounds of the formula I: | 2011-09-29 |
20110237641 | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING THESE, METHOD OF PRODUCTION AND USE - The disclosure relates to a compound of formula (I): | 2011-09-29 |
20110237642 | Process for Forming Amorphous Atorvastatin - A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solutilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin. | 2011-09-29 |
20110237643 | Identification of a Novel repressor on IFN-lambda promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-lambda gene activity - The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-λ1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-λ1 (i.e., increases the production of IFN-λ1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-λ1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-λ1 protein that promotes an anti-viral response as well as treats asthma diseases. | 2011-09-29 |
20110237644 | UBIQUITIN SPECIFIC PROTEASES RESPONSIBLE FOR MCL-1 STABILITY AND USES THEREOF - Use of a polypeptide selected from the group consisting of USP13, USP26, USP38, USP42 or USP46 as a screening tool for an agent for treating cancer. | 2011-09-29 |
20110237645 | USE OF RNAi TECHNOLOGY TO INHIBIT ASIC3 - In vitro studies using cells transfected with acid-sensing ion channel 3 (ASIC3) or acid-sensing ion channel 1 (ASIC1) cDNA, demonstrated that the miRNAs against mouse ASIC3 (miR844 and miR847) selectively inhibit mouse ASIC3, but not ASIC1 as detected by protein expression and responses to pH. When the RNAi agents, miR844 or miR847, were used in vivo, delivered into the muscle of mice using a replication-defective herpes simplex viral (HSV-1) vector, primary and secondary hyperalgesia were reduced after carrageenan-induced muscle inflammation. Accordingly, the present invention provides RNAi agents that target ASIC3, methods of preparing such RNAi agents, and methods of using them to modulate in a cell the level of ASIC3 or activity of an ASIC including at least one ASIC3. Modulation of ASIC3 activity or levels can be used for different purposes such as treating pain associated with the expression of ASIC3 and the like. | 2011-09-29 |
20110237646 | MODULATION OF TRANSTHYRETIN EXPRESSION FOR THE TREATMENT OF CNS RELATED DISORDERS - Compounds, compositions and methods are provided for modulating the expression of transthyretin in the brain, specifically the choroid plexus. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided. | 2011-09-29 |
20110237647 | INHIBITORY RNA FOR MODULATING THE MOLECULAR FUNCTION OF ZFAT GENE - The inhibitory RNA for inhibiting the expression of ZFAT gene according to this invention is a siRNA comprising a sense RNA having a base sequence of contiguous 20 to 20 bases, preferably 23 to 27 bases, of ZFAT mRNA and an anti-sense RNA having a base sequence complementary to the base sequence of the sense RNA or a shRNA comprising a double-stranded RNA (dsRNA) with the sense RNA connected to the anti-sense RNA via a loop sequence. | 2011-09-29 |
20110237648 | RNA INTERFERENCE IN SKIN INDICATIONS - The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications. | 2011-09-29 |
20110237649 | TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRTUIN 1 - Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucleotide compounds designed to inhibit the SIRT1 natural antisense transcript to patients. | 2011-09-29 |
20110237650 | TREATMENT OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO VEGF - Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients. | 2011-09-29 |
20110237651 | TREATMENT OF ERYTHROPOIETIN (EPO) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO EPO - Oligonucleotide compounds modulate expression and/or function of Erythropoietin (EPO) polynucleotides and encoded products thereof. Methods for treating diseases associated with Erythropoietin (EPO) comprise administering one or more oligonucleotide compounds designed to inhibit the EPO natural antisense transcript to patients. | 2011-09-29 |
20110237652 | Detection and destruction of cancer cells using programmed genetic vectors - In its various embodiments, the invention provides, first, a composition comprising a vector for transfecting a cell. The vector comprises a first nucleic acid encoding an antisense agent having thereon an RNA interference target for a transcript of a gene endogenous to the cell. The vector further comprises a second nucleic acid that encodes a cell-killing agent. The second nucleic acid further comprises a sequence of nucleotides transcribable into a non-coding region of a transcript of the second nucleic acid, such that the non-coding region becomes an RNA interference target for the antisense agent. In the transfected cell, the vector operates to interfere with the expression of the cell-killing agent unless and until the vector senses certain endogenous gene signals, whereupon it releases the cell-killing agent. Second, the invention provides a method of treating a disease in a patient by killing cells responsible for the disease, the method comprising administering the vector to the patient until the disease, or a symptom thereof, is ameliorated. | 2011-09-29 |
20110237653 | RNA VECTOR THERAPY METHOD - The innovative treatment method described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver a wide variety of cellular ribonucleic acid molecules to specific types of cells in the body. Utilizing probes on the exterior of the transport devices, the transport devices locate a specific type of cell in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery devices insert their payload of cellular ribonucleic acid molecules into the target cells. By delivering cellular ribonucleic acid molecules into specific cells a wide variety of protein deficiencies are correctable, gene expression is capable of being modulated, and telomere synthesis is enhanced. | 2011-09-29 |
20110237654 | METHOD TO INHIBIT CELL GROWTH USING OLIGONUCLEOTIDES - Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more oligonucleotides which share at least 33% but less than 100% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, atopic dermatitis, or hyperproliferative diseases of other epithelia and methods for reducing photoaging, or oxidative stress or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are also disclosed. The compositions and methods are also useful for treating other cancers, such as for example pancreatic cancer and eradicating cancer stem cells. | 2011-09-29 |
20110237655 | RECOMBINANT PLATELET COLLAGEN RECEPTOR GLYCOPROTEIN VI AND ITS PHARMACEUTICAL USE - The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPVI can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases. | 2011-09-29 |
20110237656 | Method of Selectively Inhibiting the Activity of ACAT1 in the Treatment of Alzheimer's Disease - The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2. | 2011-09-29 |
20110237657 | Transport-Mediating Colloidal Pharmaceutical Compounds - The invention relates to transport mediator-bonded colloids comprising pharmaceutical substances or fluorescence markers, to a method for the production thereof, and to a pharmaceutical preparation comprising said compounds. | 2011-09-29 |
20110237658 | COMPOUND AND METHOD FOR THE TREATMENT OF PAIN - The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. | 2011-09-29 |
20110237659 | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS - The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. | 2011-09-29 |
20110237660 | ORAL COMPOSITION - A composition which is adapted for oral consumption comprising daidzein and an anthocyanidin, wherein the weight ratio of daidzein to anthocyanidin is in the range of from 1:1 to 1:100, wherein the daidzein is in the form of a pre-prepared aqueous dispersion, and wherein the composition is free of soy protein, which can exhibit an anti-inflammatory effect in skin, the use of a composition containing daidzein and an anthocyanidin for obtaining an anti-inflammatory effect in the skin and a method of reducing skin inflammation through the oral consumption of the composition. | 2011-09-29 |
20110237661 | Supplement Composition and Method of Use - The present invention relates to a dietary supplement composition made of: linolinic expeller pressed soybean oil in the range of 65%-85%, Omega 3 (18/12) fish oil 15%-35%, and 1%-20% alpha-tocopherol and a method to use this composition to supplement the diet of a domestic animal, such as a canine or an equine. | 2011-09-29 |
20110237662 | Use of Statins to Inhibit Inflammation and Vascular Disease - The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. | 2011-09-29 |
20110237663 | Method for treating Philadelphia-negative myeloproliferative syndromes - A method for treating Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof, in combination with N-hydroxyurea to a patient in need of such a treatment, is described. The diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride in combination with N-hydroxyurea induces positive therapeutic responses in patients refractory to the N-hydroxyurea monotherapy and/or whose therapeutic response to monotherapy with the same dose of N-hydroxyurea is unsatisfactory. | 2011-09-29 |
20110237664 | SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES - This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC. | 2011-09-29 |
20110237665 | Agrochemical Composition Comprising Pesticide and UV Absorber - The present invention relates to an agrochemical composition comprising pesticide and UV absorber, and the abovementioned UV absorbers. The invention furthermore relates to the use of the UV absorbers in agrochemical compositions. It moreover relates to a method of controlling phytopathogenic fungi and/or undesirable plant growth and/or undesirable insect or mite infestation and/or of regulating plant growth. | 2011-09-29 |
20110237666 | HYDROXYBUTYRATE ESTER AND MEDICAL USE THEREOF - A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia. | 2011-09-29 |
20110237667 | Compositions Containing Diethanol Amine Esterquats - The invention relates to compositions containing one or more compounds of the formula (1), wherein R | 2011-09-29 |
20110237668 | CHOLINE SALTS OF SUCCINIC ACID FOR THE TREATMENT OF DEPRESSION, ANXIETY, SCHIZOPHRENIA, SLEEP DISORDER, AND EPILEPSY - The present invention relates to compositions and methods for treatment of depression, anxiety, schizophrenia, sleep disorder, or epilepsy comprising monocholine salt of succinic acid of a formula (I) or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutically acceptable salt is dicholine salt of succinic acid of a formula (II). | 2011-09-29 |
20110237669 | Polyunsaturated Fatty Acids Interactions and Oxidative Stress Disorders - This invention relates to the identification and treatment of the effects of products derived from oxidative pathways for polyunsaturated fatty acid (PUFA) metabolism, i.e., oxidative stress in a patient by monitoring the metabolism of DHA or by administering DHA. | 2011-09-29 |
20110237670 | IMPROVEMENT OF NORMAL COGNITIVE FUNCTION - The present invention shows that administration of L-lysine enhances cognitive performance in healthy individuals directly and these improvements persist if L-lysine is continuously administrated. However, when administration is interrupted the cognitive performance returns to baseline. | 2011-09-29 |
20110237671 | COSMETIC COMPOSITION COMPRISING VITAMIN U AS ACTIVE INGREDIENT FOR HEALING WOUNDS AND REDUCING WRINKLES - Disclosed is a method of using a composition comprising vitamin U as an active ingredient to heal skin wound and inhibit collagenase. The method includes the step of applying an effective amount of the composition on human skin. The vitamin U is included at a concentration of 0.00001-30.0% (w/w) by the total weight of the composition. | 2011-09-29 |
20110237672 | Use of a cysteine-containing substance to increase the ventilatory activity and erythropoietin production - The invention deals with the use of cysteine, a cysteine precursor substance or a cysteine derivative or a cysteine-containing substance to increase the oxygen supply to the tissue by increasing the ventilatory activity and/or by increasing the production of the blood-forming hormone erythropoietin (EPO), especially for the treatment of aging-related or disease-related conditions associated with a decreased oxygen supply to the tissue, especially in elderly subjects, in the treatment of malignant diseases and in cardiorespiratory diseases. | 2011-09-29 |
20110237673 | Novel NIDDM Regimen - The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone. | 2011-09-29 |
20110237674 | TOPICAL NSAID COMPOSITIONS HAVING SENSATE COMPONENT - Topical pharmaceutical compositions comprising a topically administrable NSAID, a sensate agent and optionally a self-warming system, when administered to a patient in need thereof, provide significant improvements in the rate and extent of skin absorption, as well as impart a sensation of rapid and complete relief from pain. | 2011-09-29 |
20110237675 | PHARMACEUTICAL FORMULATIONS - The present invention provides a modified release formulation comprising an active agent in a hydrophilic polymer matrix wherein the active agent is a salt of fenofibric acid wherein the release rate of the formulation in an in vitro dissolution is substantially independent of the ionic strength of the dissolution media. | 2011-09-29 |
20110237677 | Inhibitors - The invention relates to inhibitors of tissue transglutaminase II activity and their use as a tocolytic agent. | 2011-09-29 |
20110237678 | N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES - A compound of general formula (I). A process for preparing this compound. A fungicidal composition comprising a compound of general formula (I). A method for treating plants by applying a compound of general formula (I) or a composition comprising it. | 2011-09-29 |
20110237679 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - Compounds, salts thereof, and tautomers thereof are disclosed. Compositions that include the compounds are disclosed. Methods of making and using the compounds are also disclosed. | 2011-09-29 |
20110237680 | CRYSTAL FORMS OF O-DESMETHYLVENLAFAXINE FUMARATE - Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical composition thereof. | 2011-09-29 |
20110237681 | INHALABLE EPINEPHRINE - The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action. | 2011-09-29 |